Our study investigated how the inhibition of MED12 and CDK8/19 subunits affects cancer signaling pathways and cell processes in prostate cancer, focusing on AR activity and cell responsiveness to enzalutamide. The gene discussed is CDK8; the disease is prostate cancer.